(MDT) Medtronic - Ratings and Ratios
Pacemaker, Defibrillator, Stent, Pump, Monitor
Dividends
| Dividend Yield | 2.78% |
| Yield on Cost 5y | 2.90% |
| Yield CAGR 5y | 5.18% |
| Payout Consistency | 93.8% |
| Payout Ratio | 50.1% |
| Risk via 10d forecast | |
|---|---|
| Volatility | 19.7% |
| Value at Risk 5%th | 30.3% |
| Relative Tail Risk | -6.55% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.85 |
| Alpha | 13.20 |
| CAGR/Max DD | 0.56 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.491 |
| Beta | 0.443 |
| Beta Downside | 0.602 |
| Drawdowns 3y | |
|---|---|
| Max DD | 22.77% |
| Mean DD | 6.03% |
| Median DD | 5.14% |
Description: MDT Medtronic December 02, 2025
Medtronic plc (NYSE:MDT) designs, manufactures, and markets a broad range of device-based therapies across five primary segments: Cardiovascular (pacemakers, defibrillators, ablation tools, remote monitoring), Neuroscience (spinal-cord stimulators, brain-modulation systems, drug-infusion implants), Medical Surgical (AI-enhanced video analytics, robotic platforms, stapling and sealing instruments), Diabetes (insulin pumps, CGM sensors, smart pens), and a suite of ancillary products for a wide array of specialists from cardiologists to ENT surgeons. The company operates globally, with a strong footprint in the United States, Ireland, and other international markets.
Key data points to watch: FY 2023 revenue reached roughly $30 billion, with an operating margin near 28%; the Cardiovascular and Diabetes units together contributed over 55% of total sales, reflecting the aging-population tailwinds and rising prevalence of chronic disease. A notable sector driver is the accelerating adoption of remote patient monitoring, which has boosted recurring-revenue streams and improved reimbursement rates under Medicare’s Chronic Care Management program. Additionally, Medtronic’s exposure to the “value-based care” shift means that procedural volume growth may be tempered by bundled-payment models, making cost-efficiency initiatives a critical performance lever.
For a deeper dive into MDT’s valuation metrics, competitive positioning, and scenario analysis, you might explore the detailed research available on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income (4.76b TTM) > 0 and > 6% of Revenue (6% = 2.09b TTM) |
| FCFTA 0.06 (>2.0%) and ΔFCFTA -0.41pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 40.45% (prev 31.04%; Δ 9.41pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.08 (>3.0%) and CFO 7.11b > Net Income 4.76b (YES >=105%, WARN >=100%) |
| Net Debt (27.82b) to EBITDA (9.27b) ratio: 3.00 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.42 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (1.29b) change vs 12m ago 0.05% (target <= -2.0% for YES) |
| Gross Margin 62.27% (prev 65.05%; Δ -2.78pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 38.32% (prev 36.65%; Δ 1.68pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 9.03 (EBITDA TTM 9.27b / Interest Expense TTM 710.0m) >= 6 (WARN >= 3) |
Altman Z'' 3.32
| (A) 0.15 = (Total Current Assets 24.00b - Total Current Liabilities 9.94b) / Total Assets 91.35b |
| (B) 0.35 = Retained Earnings (Balance) 32.07b / Total Assets 91.35b |
| (C) 0.07 = EBIT TTM 6.41b / Avg Total Assets 90.69b |
| (D) 0.65 = Book Value of Equity 27.80b / Total Liabilities 42.49b |
| Total Rating: 3.32 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 64.31
| 1. Piotroski 5.0pt |
| 2. FCF Yield 3.43% |
| 3. FCF Margin 14.98% |
| 4. Debt/Equity 0.60 |
| 5. Debt/Ebitda 3.00 |
| 6. ROIC - WACC (= 0.88)% |
| 7. RoE 9.83% |
| 8. Rev. Trend 76.34% |
| 9. EPS Trend 12.99% |
What is the price of MDT shares?
Over the past week, the price has changed by -3.77%, over one month by +12.12%, over three months by +9.93% and over the past year by +24.43%.
Is MDT a buy, sell or hold?
- Strong Buy: 12
- Buy: 5
- Hold: 13
- Sell: 1
- Strong Sell: 1
What are the forecasts/targets for the MDT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 110.3 | 8.8% |
| Analysts Target Price | 110.3 | 8.8% |
| ValueRay Target Price | 111.1 | 9.6% |
MDT Fundamental Data Overview December 05, 2025
P/E Trailing = 27.6341
P/E Forward = 18.3486
P/S = 3.7628
P/B = 2.7231
P/EG = 3.9207
Beta = 0.739
Revenue TTM = 34.76b USD
EBIT TTM = 6.41b USD
EBITDA TTM = 9.27b USD
Long Term Debt = 27.62b USD (from longTermDebt, last quarter)
Short Term Debt = 1.42b USD (from shortTermDebt, last quarter)
Debt = 29.10b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 27.82b USD (from netDebt column, last quarter)
Enterprise Value = 151.56b USD (130.79b + Debt 29.10b - CCE 8.33b)
Interest Coverage Ratio = 9.03 (Ebit TTM 6.41b / Interest Expense TTM 710.0m)
FCF Yield = 3.43% (FCF TTM 5.21b / Enterprise Value 151.56b)
FCF Margin = 14.98% (FCF TTM 5.21b / Revenue TTM 34.76b)
Net Margin = 13.71% (Net Income TTM 4.76b / Revenue TTM 34.76b)
Gross Margin = 62.27% ((Revenue TTM 34.76b - Cost of Revenue TTM 13.11b) / Revenue TTM)
Gross Margin QoQ = 60.32% (prev 57.66%)
Tobins Q-Ratio = 1.66 (Enterprise Value 151.56b / Total Assets 91.35b)
Interest Expense / Debt = 0.62% (Interest Expense 181.0m / Debt 29.10b)
Taxrate = 13.47% (215.0m / 1.60b)
NOPAT = 5.54b (EBIT 6.41b * (1 - 13.47%))
Current Ratio = 2.42 (Total Current Assets 24.00b / Total Current Liabilities 9.94b)
Debt / Equity = 0.60 (Debt 29.10b / totalStockholderEquity, last quarter 48.65b)
Debt / EBITDA = 3.00 (Net Debt 27.82b / EBITDA 9.27b)
Debt / FCF = 5.34 (Net Debt 27.82b / FCF TTM 5.21b)
Total Stockholder Equity = 48.49b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.22% (Net Income 4.76b / Total Assets 91.35b)
RoE = 9.83% (Net Income TTM 4.76b / Total Stockholder Equity 48.49b)
RoCE = 8.42% (EBIT 6.41b / Capital Employed (Equity 48.49b + L.T.Debt 27.62b))
RoIC = 7.23% (NOPAT 5.54b / Invested Capital 76.64b)
WACC = 6.36% (E(130.79b)/V(159.89b) * Re(7.65%) + D(29.10b)/V(159.89b) * Rd(0.62%) * (1-Tc(0.13)))
Discount Rate = 7.65% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -33.33 | Cagr: -1.68%
[DCF Debug] Terminal Value 78.53% ; FCFE base≈5.32b ; Y1≈5.41b ; Y5≈5.93b
Fair Price DCF = 81.62 (DCF Value 104.63b / Shares Outstanding 1.28b; 5y FCF grow 1.39% → 3.0% )
EPS Correlation: 12.99 | EPS CAGR: -0.20% | SUE: 2.62 | # QB: 4
Revenue Correlation: 76.34 | Revenue CAGR: 3.90% | SUE: 1.26 | # QB: 2
EPS next Quarter (2026-01-31): EPS=1.34 | Chg30d=-0.010 | Revisions Net=-14 | Analysts=27
EPS current Year (2026-04-30): EPS=5.64 | Chg30d=+0.017 | Revisions Net=+17 | Growth EPS=+2.7% | Growth Revenue=+7.5%
EPS next Year (2027-04-30): EPS=6.11 | Chg30d=+0.042 | Revisions Net=+23 | Growth EPS=+8.4% | Growth Revenue=+5.6%
Additional Sources for MDT Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle